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Abstract: 
Background: Preterm birth remains a common cause of neonatal mortality with a 
disproportionate burden occurring in low and middle-income countries.  Meta-analyses of low-
dose aspirin to prevent preeclampsia suggest that the incidence of preterm birth may be 
decreased, particularly if initiated before 16 weeks.  
Methods: We conducted a multi-country randomized, double masked trial of aspirin (81 mg) 
daily compared to placebo initiated between 6 weeks and 0 days of pregnancy and 13 weeks 
and 6 days of pregnancy in nulliparous women. Prior to randomization, ultrasound confirmed the 
gestational age and presence of a singleton viable pregnancy. The primary outcome was 
preterm birth, defined as delivery at or after 20 weeks and prior to 37 weeks gestational age.  
Results:  A total of 11,976 women in 6 countries (India, Guatemala, Pakistan, Kenya, Zambia, 
Democratic Republic of Congo) were randomly assigned to aspirin (5,990 women) or placebo 
(5,986 women). Preterm birth occurred in 11.6% of women randomized to aspirin and 13.1% 
randomized to placebo (RR, 0.89; 95% CI, 0.81 to 0.98). Women who took aspirin were also 
less likely to deliver before 34 weeks gestation (3.3% vs 4.0%; RR, 0.75; 95%CI, 0.61 to 0.93) 
or experience perinatal mortality (45.7/1000 vs 53.6/1000; RR, 0.86; 95%CI, 0.73 to 1.00). 
Adverse maternal events were similar between the two groups. 
Conclusions:  In nulliparous women with singleton pregnancies, low dose aspirin initiated 
between 6 weeks and 0 days and 13 weeks and 6 days results in lower rates of preterm delivery 
before 37 weeks and before 34 weeks.  
Trial Registration: Funded by the Eunice Kennedy Shriver National Institute of Child Health 
and Human Development; NCT ASPIRIN ClinicalTrials.gov 02409680/Clinical Trials Registry-
India CTRI/2016/05/006970. 
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Background: 
Preterm birth, defined as delivery prior to 37 weeks, remains a predominant driver of infant 
mortality worldwide with the greatest burden of disease occurring in low and middle-income 
countries1,2.  Though improvements in neonatal care have resulted in improved survival3, this 
care is often limited or unavailable in the regions with the highest burden of mortality. Beyond 
the newborn period, longitudinal adverse effects in health and socioeconomic outcomes have 
been associated with preterm delivery compared to individuals delivered at term4–6.  Despite 
numerous trials of preventive and tocolytic therapies, an effective strategy for the prevention of 
preterm birth has proved elusive, beyond a few at-risk groups7,8. 
Meta-analyses and systematic reviews of trials of low-dose aspirin in pregnant women for the 
purpose of prevention of preeclampsia have suggested that women receiving aspirin have a 
lower occurrence of preterm birth9–12.  This effect may be greater when low dose aspirin is 
begun before 16 weeks of gestation13. Though promising as a strategy, a large definitive trial of 
low-dose aspirin initiated early in pregnancy with the prevention of preterm birth as the primary 
outcome has not been conducted.  The Aspirin (Aspirin Supplementation for Pregnancy 
Indicated risk Reduction In Nulliparas-ClinicalTrials.gov Identifier: NCT02409680/Clinical Trials 
Registry-India CTRI/2016/05/006970) trial was therefore designed to test the hypothesis that 
low-dose aspirin (81 mg) administered daily initiated between 6 weeks 0 days and 13 weeks 6 
days reduces the incidence of preterm delivery amongst nulliparous women with a singleton 
pregnancy. 
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Trial Oversight: 
We conducted a multinational, randomized double-masked, placebo-controlled trial assessing 
daily low- dose aspirin (81 mg) begun between 6 weeks and 0 days and 13 weeks and 6 days 
until 36 weeks and 0 days of pregnancy to prevent preterm birth before 37 weeks amongst 
nulliparous women with a singleton pregnancy.  Nulliparous women were selected as they have 
a higher rate of preterm birth than multiparous women14 and are unlikely to undergo treatment to 
prevent prematurity due to a lack of obstetrical history.  The trial was conducted by the NICHD 
Global Network for Women’s and Children’s Health Research in 7 sites in 6 countries- India (2 
sites), Pakistan, Zambia, Democratic Republic of Congo, Guatemala and Kenya - between 
March 2016 and April 2019.   The trial protocol (available with the full text of this article at 
NEJM.org) has been previously published15.  Prior to the initiation of the trial, the protocol was 
approved by the relevant ethics committees and regulatory agencies of each country as well as 
the ethics committees of the United States-based collaborators and that of the Research 
Triangle Institute (RTI) International.  The trial was conducted in accordance with Good Clinical 
Practice Guidelines.  An external independent data and safety monitoring board oversaw the 
conduct of the trial and monitored the occurrence of serious adverse events.   No formal interim 
analyses were planned nor conducted.  
Trial initiation, data management, safety monitoring, drug/placebo supply procurement, and 
supply chain management, as well as development of the statistical plan and performance of 
the analyses were performed by the trial’s data coordinating center, RTI International.  The trial 
protocol and the manuscript were written by the lead author, trial statisticians, and members of 
the steering committee (NICHD representatives, RTI International researchers and site research 
representatives).  All authors attest to the accuracy and completeness of the data and the 
fidelity of the trial to the protocol. 
Screening and recruitment: 
Each site established a plan to screen pregnant women residing within the study communities. 
Nulliparous women between 6 weeks and 0 days and 13 weeks and 6 days, who were between 
14 (18 when required by individual ethics boards) and 40 years of age, were identified and were 
individually consented for participation by trained staff.    We excluded women who had any of 
the following by medical history:  allergy or contraindication to aspirin, previously taken aspirin 
therapy for more than 7 days during this pregnancy, multiple gestations, history of more than 
two first trimester losses, or medical conditions for which low-dose aspirin therapy is currently 
indicated (e.g. diabetes and hypertension).  Non-excluded women then underwent a medical 
screening for additional eligibility criteria which included: blood pressure (BP > 140/90 were 
excluded), hemoglobin assessment (<7.0 g/dl were excluded) and ultrasound for gestational 
age dating.  Women were also excluded from the trial if the ultrasound demonstrated absence 
of a fetal heartbeat, multiple gestations, and/or presence of a fetal anomaly.  The crown-rump 
length and last menstrual period were entered into a smartphone application to determine the 
gestational age in accordance with American College of Obstetrics and Gynecology (ACOG) 
guidance16.  
Randomization and trial regimen: 
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Eligible and consented women were randomly assigned in a 1:1 ratio to a daily regime of either 
81 mg of aspirin or placebo. The aspirin tablets and placebo were manufactured by Morepen 
Laboratories in Parwanoo, Himachal Pradesh, India and Helix Pharma Limited located in 
Karachi, Pakistan.  Packaging and distribution were handled by Bilcare Research Global Clinical 
Supplies.  The placebo tablets were identical to the aspirin tablets in size, weight, and 
appearance. Certificates of analysis following USP reference standards were performed for 
each lot produced. Stability testing at 6, 12, 18, and 24 months for each lot was performed by 
high performance liquid chromatography for active ingredients and appearance by RTI 
International. The randomization sequence was developed for each site by the data 
coordinating center using a computer algorithm based on randomly permuted block design with 
varied block sizes.  Women then received sequentially numbered pre-packaged 2-week 
medication allotments. These were exchanged every 2 weeks by study personnel and an 
assessment of compliance, side-effects, interval medical contacts, and concomitant medications 
were documented. Throughout the study, research staff and local health providers were masked 
to treatment.  Blood pressure assessments were made between 16 to 20 weeks, 28 to 30 
weeks and then biweekly beginning at 34 weeks until delivery. Repeat hemoglobin assessments 
were obtained between 26-30 weeks. Maternal and neonatal outcomes were obtained through 
42 days using a previously described registry 17.  
Outcomes:  
The primary outcome of this study was preterm birth, which was defined as any delivery at or 
after 20 weeks 0 days and prior to 37 weeks and 0 days.  Predefined secondary maternal 
outcomes were hypertensive disorders of pregnancy, preterm (<34 weeks’ gestation) 
hypertensive disorders of pregnancy, vaginal bleeding, antepartum hemorrhage, postpartum 
hemorrhage, maternal mortality through 42 days postpartum, and late abortion.  Secondary 
fetal/neonatal outcomes were perinatal mortality, preterm birth before 34 weeks, preterm birth 
before 28 weeks, small for gestational age as defined by the Intergrowth standard18, birthweight 
<1500 gm, birthweight <2500 gm, spontaneous abortion, stillbirth (both non-macerated and total 
stillbirth), fetal loss (defined as birth between 16-20 weeks and perinatal mortality between 20 
weeks to <7 days post-delivery), and medical termination of pregnancy. All staff were trained in 
the study procedures, and methods of internal quality checks were designed to ensure high 
quality data.  Definitions of secondary outcomes are provided in the Supplementary Appendix.  
Review of outcomes and data consistency was performed in a masked fashion prior to data lock 
and analysis. Quality assessment of the ultrasound images was performed contemporaneously 
on 10% of studies with feedback provided to the individual sonographer.   
Statistical Analysis: 
The expected incidence of the primary outcome was conservatively estimated to be 8%1.  
Assuming a 5% risk of miscarriage and a 2% rate of lost to follow up, the sample size of 11,920 
participants (5,960 per arm) would provide 90% power to detect a 20% reduction in the 
incidence of preterm birth in women treated with low-dose aspirin assuming a two-sided type 
one error of 5%. Recognizing that missing data was likely to occur due to miscarriage and/or 
medical termination of pregnancy, we planned a priori to perform a modified intent to treat 
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analysis for the primary outcome including only women who achieved a pregnancy of 20 weeks 
and beyond (See the Supplementary Appendix). Women who were subsequently determined to 
be ineligible were excluded from the analysis as part of the modified intent to treat approach. 
We also pre-specified a sensitivity analysis within a per-protocol population, defined primarily as 
a participant who consumed 90% of her prescribed regimen (See the Supplementary Appendix).  
Analyses of all binary outcomes included a Cochran-Mantel-Haenszel test stratified by site to 
formally test the primary hypothesis followed by generalized linear model-based sensitivity 
analyses that explore the treatment by site interaction, adjustment for key demographic, and 
clinical variables.  Analyses of secondary outcomes are exploratory in nature and therefore, p-
values and confidence intervals are provided for descriptive purposes only and no adjustment 
for multiple comparisons were made. Serious adverse events were assessed on all women who 
were allocated to drug or placebo (safety population). Further description of the statistical 
methods is provided in the Supplementary Appendix. 
Results: 
Characteristics of the participants:  
From March 2016 through June 2018, a total of 14361 women underwent screening for eligibility 
after providing informed consent. A total of 2385 women were excluded or declined 
randomization and the remaining 11976 consented and were randomized: 5990 were assigned 
to low-dose aspirin and 5986 were allocated to placebo (Figure 1). The low-dose aspirin group 
had 5787 women who were in the modified intent to treat (MITT) population and the placebo 
group contained 5771.  Baseline characteristics and site of delivery were similar between the 
two groups (Table 1). Overall adherence to medication or placebo defined as taking > 90% of 
the prescribed medications was high (MITT population overall 84.9%: aspirin 85.3% vs placebo 
84.4%). The quality of the drug was evaluated upon manufacture and episodic assessments of 
stability by a masked third party demonstrated appropriate potency throughout the duration of 
the study (See the Supplementary Appendix). 
Primary outcome 
The primary outcome of preterm delivery before 37 weeks occurred in 11.6% of women 
receiving aspirin and 13.1% of women in the placebo group (RR, 0.89; 95%CI, 0.81 to 0.98). To 
prevent one preterm delivery, 66 women (NNT) would need to be prescribed aspirin. In the per 
protocol population, the primary outcome occurred in 10.9% of women receiving aspirin and 
12.3% of women in the placebo group (RR, 0.89; 95% CI, 0.80 to 0.99).  No interaction between 
the study site and the primary outcome was seen in either of these analyses.  The intent to treat 
outcomes are noted to be similar to the modified intent to treat analyses and are provided in the 
Supplementary Appendix.   
Secondary outcomes 
Preterm delivery before 34 weeks was reduced in women who were randomized to aspirin 
compared to those randomized to placebo (3.3% vs. 4.0%; RR, 0.75; 95%CI, 0.61 to 0.93). 
Preterm delivery before 28 weeks trended lower in women who received aspirin compared to 
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placebo but did not achieve statistical significance (0.9% vs. 1.3%; RR, 0.72; 95%CI, 0.51 to 
1.02).  Perinatal mortality occurred less frequently among women randomized to aspirin 
compared to those who received placebo (aspirin 45.7/1000 vs placebo 53.6/1000; RR, 0.86; 
95%CI, 0.73 to 1.00).  The incidence of overall hypertensive disorders of pregnancy was not 
different between women randomized to aspirin (6.1%) and those who received placebo (5.6%) 
(RR, 1.08; 95%CI, 0.94 to 1.25); however, the incidence of women who were delivered before 
34 weeks with hypertensive disorders of pregnancy was significantly lower in women 
randomized to aspirin (0.1%) compared to women randomized to placebo (0.4%)(RR, 0.38; 
95%CI, 0.17 to 0.85). No differences in the occurrence of fetal growth abnormalities defined as 
a birthweight <2500 gm or <1500 gm were noted between the two groups (Table 2). Fetal loss 
(Stillbirth and abortion at or after 16 weeks) was also lower among women randomized to 
aspirin (52.1/1000) compared to women who received placebo (60.8/1000)(RR, 0.86; 95% CI, 
0.74 to 1.00) Other maternal and fetal/neonatal outcomes were similar between the two groups. 
Maternal and Fetal/Neonatal Serious Adverse Events 
Overall serious adverse events were similar between the groups (aspirin 14.0% vs placebo 
14.4%- RR, 0.94; 95%CI, 0.84 to 1.05).  Broad categories of adverse events are compared 
between groups and are shown in table 3A (maternal) and 3B (fetal/neonatal).  No differences in 
maternal bleeding complications (antepartum hemorrhage, postpartum hemorrhage, or upper 
gastrointestinal bleeding) were detected between the groups. The proportion of women who had 
a second hemoglobin < 7.0 g/dl or had a 3.5 g/dl drop also did not differ between groups.  
Maternal mortality was high (176/100000) compared to high-income countries, though no 
observable differences were seen between groups. Fetal/neonatal serious adverse events did 
not differ between women who received aspirin and those who received placebo. No differences 
were seen in the rates of overall anomalies, gastroschisis or neonatal death. 
 Discussion 
In this randomized double masked controlled trial, nulliparous women with a singleton 
pregnancy who were allocated to low-dose aspirin between 6 weeks and 0 days and 13 weeks 
and 6 days until 36 weeks gestation were 11% less likely to deliver before 37 weeks.  Similarly, 
the risk of preterm delivery prior to 34 weeks was lowered by 25% and perinatal mortality was 
decreased by 16%.  Importantly, we saw no increase in either maternal or fetal serious adverse 
events between women prescribed low-dose aspirin compared to women who received placebo.  
These outcomes are consistent with several meta-analyses which had demonstrated similar 
levels of reduction of preterm birth and perinatal mortality 9,19,20 .  Because of the large sample 
size, this trial was able to demonstrate these benefits definitively in a diverse group of women in 
six low and middle- income countries. The simple eligibility criteria used as part of this trial 
allows this intervention to potentially be applied to diverse groups of pregnant women in multiple 
settings and may be particularly relevant in low- and middle-income countries. The low cost and 
demonstrated tolerability of aspirin in this population suggests that this intervention can be 
readily and safely adopted across a span of clinical sites. 
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Several limitations should be noted.  First the applicability of this intervention to other groups of 
women beyond nulliparas with singleton gestations remains unclear.  Secondly, prior meta-
analyses have suggested that higher doses of aspirin (>100 mg) may further lower the 
incidence of preeclampsia10. The optimal dose and time of initiation for the prevention of 
preterm birth remains unclear. Finally, though aspirin has been endorsed for the prevention of 
preeclampsia at term, we were only able to demonstrate a decrease in the incidence of preterm 
(<34 weeks) hypertensive disorders of pregnancy.  This failure to demonstrate a difference in 
term preeclampsia may be related to both our definition of hypertensive disorders of pregnancy 
and the settings in which we performed this study. The diagnosis of preeclampsia most 
commonly occurs at the time of the birth admission.  In the care settings for this trial, 
measurement of blood pressure and assessment of proteinuria does not routinely occur, 
potentially leading to an ascertainment bias.  Recognizing this challenge in our care settings, we 
chose to use an expansive diagnosis of hypertensive disorders (See the Supplementary 
Appendix) that may have led to imprecision in this outcome. Nonetheless, our trial of aspirin in 
pregnancy is similar to other large trials that have likewise failed to demonstrate a benefit in the 
decreasing in the incidence of preeclampsia at term but noted effects earlier in pregnancy21–23 .  
In conclusion, this trial demonstrates that the administration of aspirin at a dose of 81 mg 
beginning between 6 weeks 0 days and 13 weeks 6 days through 36 weeks resulted in a 
significantly lower incidence of preterm birth amongst women with a singleton pregnancy in low 
and middle-income countries.  
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Figure 1. Randomization and Follow-up in the ASPIRIN Trial 
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 Excluded from analysis (n=203)              
    Ineligible participants (n=16)  
     Lost to follow-up prior to delivery (n=15) 
     Pregnancy outcome < 20 weeks (n=172) 
Analysed: Intent to Treat (n=5,974) 
 Excluded from analysis (n=16)              
    Ineligible participants (n=16)  
 
 
Lost to follow-up (n=15)  
 Lost to follow-up prior to delivery (n=15) 
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Discontinued intervention (n=89) 
 Withdrew consent (n=51) 
 Participant moved away from study area (n=20)  
 Investigator terminated participant (n=18) 
 
 
 Allocated to Aspirin (n=5,990) 
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Table 1. Baseline and Site of Delivery Characteristics (Intent to Treat Population) 
Characteristic Aspirin Placebo 
Modified Intent to Treat Population 5,974 5,979 
Maternal age (years), n (%)   
< 20 2,320 (38.8) 2,357 (39.4) 
20 – 29 3,523 (59.0) 3,487 (58.3) 
> 29 131 (2.2) 135 (2.3) 
Projected gestational age at enrollment (weeks), Median 
(P25, P75) 
10.0 (8.6, 
12.0) 
10.1 (8.6, 
12.0) 
Maternal education, n (%)   
No formal schooling 875 (14.6) 872 (14.6) 
1-6 years of schooling 876 (14.7) 888 (14.9) 
7-12 years of schooling 3,574 (59.8) 3,567 (59.7) 
≥ 13 years of schooling 648 (10.8) 651 (10.9) 
Maternal height (cm), Mean (StdDev) 153.2 (6.9) 153.1 (7.0) 
Maternal weight (Kg), Mean (StdDev) 49.3 (9.0) 49.2 (8.7) 
Maternal BMI (Kg/m2), Mean (StdDev) 21.1 (3.8) 21.0 (3.7) 
Antenatal care visits, Median (P25, P75) 5 (4, 6) 5 (4, 6) 
Delivery attendant, n (%)   
Physician 2,990 (50.2) 2,962 (49.8) 
Nurse/Nurse midwife 2,284 (38.4) 2,277 (38.3) 
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Characteristic Aspirin Placebo 
Traditional birth attendant 472 (7.9) 476 (8.0) 
Family/Self/Other 208 (3.5) 229 (3.9) 
Delivery location, n (%)   
Hospital 3,541 (59.5) 3,554 (59.8) 
Clinic/Health center 1,854 (31.1) 1,798 (30.2) 
Home/Other 561 (9.4) 594 (10.0) 
Delivery mode, n (%)   
Vaginal 4,278 (71.8) 4,348 (73.1) 
C-Section 1,523 (25.6) 1,441 (24.2) 
Miscarriage 114 (1.9) 131 (2.2) 
MTP 41 (0.7) 26 (0.4) 
 
Characteristics were compared between study arms using chi-square tests for categorical 
measures, t-tests for continuous data, and Wilcoxon rank sum tests for ordinal data. All p-values 
comparing treatment groups were greater than 0.05. 
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Table 2. Primary, Secondary, and Other Outcomes 
Outcome Aspirin Placebo p-Value4 RR (95% CI)5 
Primary Outcome     
Preterm delivery1, n/N (%) 668/5,780 
(11.6) 
754/5,764 (13.1) 0.012 0.89 (0.81, 0.98) 
Secondary Efficacy Outcomes     
Hypertensive disorders1, n/N (%) 352/5,780 (6.1) 325/5,764 (5.6) 0.30 1.08 (0.94, 1.25) 
Small for gestational age1, n/N (%) 1,506/5,492 
(27.4) 
1,564/5,467 
(28.6) 
0.17 0.95 (0.90, 1.01) 
Perinatal mortality1, n/N (Rate/1000) 264/5,779 
(45.7) 
309/5,763 (53.6) 0.048 0.86 (0.73, 1.00) 
Other Maternal Outcomes of Interest     
Vaginal bleeding2, n/N (%) 214/5,933 (3.6) 246/5,940 (4.1) 0.13 0.87 (0.73, 1.04) 
Antepartum hemorrhage1, 6, n/N (%) 26/5,761 (0.5) 25/5,746 (0.4) 0.90 1.03 (0.60, 1.79) 
Postpartum hemorrhage3, 6, n/N (%) 54/5,928 (0.9) 43/5,907 (0.7) 0.27 1.25 (0.84, 1.86) 
Maternal mortality through 42 days2, 6, 
n/N (Rate/100,000 deliveries) 
9/5,958 (151) 12/5,948 (202) 0.51 0.75 (0.32, 1.78) 
Late abortion2, n/N (Rate/1000) 23/5,819 (4.0) 30/5,808 (5.2) 0.33 0.77 (0.45, 1.31) 
Preterm and hypertensive disorders1, 6, n/N 
(%) 
8/5,780 (0.1)  21/5,764 (0.4)  0.015  0.38 (0.17, 0.85)  
Other Fetal Outcomes of Interest     
Preterm < 34 weeks of pregnancy1, n/N (%) 189/5,780 (3.3) 230/5,764 (4.0) 0.039 0.75 (0.61, 0.93) 
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Outcome Aspirin Placebo p-Value4 RR (95% CI)5 
Preterm < 28 weeks of pregnancy1, n/N (%) 54/5,780 (0.9) 75/5,764 (1.3) 0.06 0.72 (0.51, 1.02) 
Measured birth weight < 2500g1, n/N (%) 1,078/5,628 
(19.2) 
1,153/5,624 
(20.5) 
0.07 0.93 (0.87, 1.01) 
Birth weight < 2500g1, 7, n/N (%) 1,101/5,671 
(19.4) 
1,178/5,671 
(20.8) 
0.07 0.94 (0.87, 1.01) 
Measured birth weight < 1500g1, 7, n/N (%) 78/5,628 (1.4) 101/5,624 (1.8) 0.08 0.87 (0.57, 1.33) 
Birth weight < 1500g1, n/N (%) 97/5,671 (1.7) 118/5,671 (2.1) 0.15 0.79 (0.58, 1.07) 
Fetal loss2,8, n/N (Rate/1000) 303/5,818 
(52.1) 
353/5,807 (60.8) 0.039 0.86 (0.74, 1.00) 
Spontaneous abortion2, n/N (Rate/1000) 134/5,956 
(22.5) 
152/5,946 (25.6) 0.26 0.88 (0.70, 1.10) 
Stillbirth (macerated excluded)1, n/N 
(Rate/1000) 
105/5,744 
(18.3) 
119/5,717 (20.8) 0.32 0.88 (0.68, 1.14) 
All Stillbirth1, n/N (Rate/1000) 141/5,780 
(24.4) 
166/5,764 (28.8) 0.14 0.85 (0.68, 1.06) 
Medical termination of pregnancy (MTP) 2, 6, 
n/N (Rate/1000) 
42/5,956 (7.1) 30/5,946 (5.0) 0.16 1.40 (0.88, 2.23) 
 
Note: The following superscripts indicate the analysis population for each outcome variables:1 Modified intent to treat 
(mITT), 2 Intent to treat (ITT) and 3 Safety. 
4 P-values from Cochran-Mantel-Haenszel tests stratified by site. 
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5 P-values for treatment by site interaction obtained from binomial models with a log link adjusting for site, treatment 
and site by treatment interaction. If treatment by site interaction term is significant (p < 0.05), then the relative risk and 
95% confidence interval are obtained from a binomial model with a log link adjusting for site, treatment and site by 
treatment interaction and is based on the average effect across sites. If the interaction term is not significant then the 
relative risk and 95% confidence interval are obtained from a binomial model with a log link adjusting for site and 
treatment. 
6 Antepartum hemorrhage, postpartum hemorrhage, maternal mortality < 42 days, preterm and hypertensive disorders 
and MTP have low or zero cell counts for at least one site and treatment combination. For these outcomes the relative 
risks are from models adjusting for site and treatment. 
7 Data from women with Birth weight missing (N=26) or measured after 4 days are excluded (N=84). 90 babies have 
only estimated weight and 76% of stillbirths have measured birth weight. 
8 Fetal loss is defined as any death of an infant greater than 16 weeks GA and prior to 7 days post-delivery.  Any fetal 
loss (including termination of pregnancy or miscarriage) that occurs prior to 16 weeks is excluded. 
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Table 3. Serious Adverse Events 
Events Aspirin Placebo RR (95% CI)1 
p-
Value1 
Safety population, N 5,943 5,936   
Participants with at least one SAE, n 
(%) 
832 (14.0) 857 (14.4) 0.94 (0.84, 1.05) 0.25 
At least one other SAE, n (%) 495 (8.3) 514 (8.7) 0.97 (0.86, 1.09) 0.58 
3A Maternal Events     
Maternal death, n (%) 9 (0.2) 12 (0.2) 0.75 (0.32, 1.78) 0.51 
Vaginal spotting/Bleeding/Leaking pv2, 
N (%) 
10 (0.2) 10 (0.2) 1.00 (0.42, 2.39) 1.0 
Antepartum hemorrhage, n (%) 35 (0.6) 33 (0.6) 1.06 (0.66, 1.70) 0.82 
Postpartum hemorrhage, n (%) 50 (0.8) 43 (0.7) 1.24 (0.42, 3.63) 0.70 
Anemia/Drop in Hb > 3.5 g/dl2, n (%) 24 (0.4) 23 (0.4) 1.04 (0.59, 1.84) 0.89 
Preeclampsia/Eclampsia, n (%) 150 (2.5) 141 (2.4) 1.06 (0.85, 1.33) 0.59 
Preterm labor/Preterm birth evaluation 
prior to delivery2, n (%) 
45 (0.8) 56 (0.9) 0.80 (0.54, 1.19) 0.27 
Hypertension admission/Medical visit 
prior to delivery3, n (%) 
120 (2.0) 106 (1.8) 1.14 (0.88, 1.47) 0.33 
Fever/Infection2, n (%) 54 (0.9) 46 (0.8) 1.18 (0.80, 1.73) 0.42 
Other2, n (%) 57 (1.0) 57 (1.0) 1.00 (0.70, 1.44) 0.99 
3B Fetal/Infant Events     
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Events Aspirin Placebo RR (95% CI)1 
p-
Value1 
Fetal loss after 20 weeks, n (%) 142 (2.4) 162 (2.7) 0.88 (0.70, 1.09) 0.25 
Neonatal death, n (%) 163 (2.7) 190 (3.2) 0.86 (0.70, 1.05) 0.14 
Miscarriage/Abortion/MTP (medical 
termination of pregnancy), n (%) 
51 (0.9) 54 (0.9) 0.95 (0.65, 1.38) 0.77 
Other fetal anomaly2, n (%) 32 (0.5) 36 (0.6) 0.89 (0.55, 1.43) 0.63 
Gastroschisis2, n (%) 2 (0.0) 1 (0.0) 2.01 (0.18, 
22.11) 
0.60 
 
Note: The denominator for each serious adverse event is any participant included in the safety 
population and the numerator is participants with at least one SAE form indicating the specified serious 
adverse event. 
1 P-values for treatment by site interaction obtained from binomial models with a log link adjusting for 
site, treatment and site by treatment interaction, If treatment by site interaction term is significant (p < 
0.05), then the relative risk and p-value are obtained from a binomial model with a log link adjusting for 
site, treatment and site by treatment interaction and is based on the average effect across sites. If the 
interaction term is not significant then the relative risk and p-value are obtained from a binomial model 
with a log link adjusting for site and treatment. 
2 Serious adverse events with cell counts of zero for at least one site and treatment combination. For 
these SAEs the relative risks and p-values are from models adjusting for site and treatment. 
3 Serious adverse events with cell counts of zero for many sites so the models did not converge. 
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Definitions of Secondary outcomes 
Hypertensive 
disorders 
Any of the following are included as evidence of hypertensive disease:  
o Any reported SAE of preeclampsia or eclampsia. 
o MNH registry report of hypertensive disease, preeclampsia or eclampsia. 
o Reports of elevated blood pressures that meet criteria based on the ACOG 
2013 “Hypertension in Pregnancy” Task Force Report at any point after 20 weeks 
GA.   
 
The only case that will programmatically qualify for evidence of hypertension is: 
Any individual with 2 consecutive timepoints with ≥140 mm Hg systolic or ≥90 mm 
Hg diastolic where those timepoints occur more than a week (7 days) apart. The 
criteria (e.g. elevated systolic or elevated diastolic) must be consistent for the two 
consecutive visits. 
 
For individuals that do meet the above criteria: 
o If they have less no reports of elevated blood pressure or a single report of 
elevated blood pressure that is followed by a normal value, they will not be 
considered to have evidence of hypertensive disease. 
o If they have any other reports of elevated blood pressure, their outcome 
classification were adjudicated in a masked manner by clinical experts. 
Small for 
gestational age 
Defined is any newborn with weight below the 10th percentile for gestational age.  
Note that growth curves are based on Intergrowth standards to define the 
expected gestational age distribution for each site.   
Perinatal mortality This include stillbirths and deaths in the first week of life; the perinatal period 
commences at 20 completed weeks (154 days) of gestation and ends seven 
completed days after birth.  Pregnancies terminated prior to 20 completed weeks 
of gestation are treated as missing for this outcome. 
Vaginal bleeding Bleeding during pregnancy (i.e., the WHO generally defines as ‘light’ or ‘heavy’ 
bleeding based on clinical symptoms) based on self-report during the bi-weekly 
visits during the study period. 
Antepartum 
hemorrhage 
Bleeding from the genital tract at any time after the 22nd week of pregnancy and 
before the birth of the baby. There are two main causes of antepartum 
hemorrhage, placenta previa and abruption placentae.”  This outcome will be 
defined based on Question A8b from Form MN02 from the MNH Registry.  The 
event is defined as follows in the MNH Registry Manual of Operations: “Defined as 
blood loss of > 1000 cc of blood prior to delivery.”  
Postpartum 
hemorrhage 
Blood loss of 1000 ml or more from the genital tract after delivery and up to six 
weeks post-delivery.   
Maternal mortality 
through 42 days 
The death of a woman during pregnancy (i.e. conception to delivery) and the 
puerperium (i.e. up to 42 days after delivery). 
Late abortion Spontaneous fetal loss ≥ 16 weeks and prior to 20 weeks gestation (or <500 g).  
Preterm and 
hypertensive 
disorders 
Live birth or stillbirth before 34 0/7 weeks of pregnancy are completed and those 
with any evidence of hypertensive disorder 
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Fetal loss Any death of an infant greater than 16 weeks GA and prior to 7 days post-delivery.  
Any fetal loss (including termination of pregnancy or miscarriage) that occurs prior 
to 16 weeks will be excluded. 
Spontaneous 
abortion 
Premature expulsion of a non-viable fetus from the uterus at < 20 weeks 
gestation. 
Stillbirth (macerated 
excluded) 
Death of an infant prior to delivery, for a pregnancy that occurs at 20 weeks 
gestational age or greater; including only non-macerated still birth or stillbirths with 
maceration status unknown. 
All Stillbirth Death of an infant which occurs prior delivery, for a pregnancy that occurs at 20 
weeks gestation or greater 
Medical termination 
of pregnancy 
An operation or other procedure to terminate pregnancy before the fetus is viable. 
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Statistical Plan Definitions 
Safety (SAF) Population 
The safety population comprises all randomized participants who received any study treatment 
grouped by actual treatment received, irrespective of amount or duration of treatment received.  
Modified Intention to Treat (mITT) Population  
The primary analysis population is the modified intention to treat population, which includes all 
eligible randomized participants who provided any post-baseline outcome data and who 
delivered at 20 weeks gestational age or greater.  All participants were assigned to the arm to 
which they were randomized irrespective of treatment received. This population is also used for 
many of the secondary analyses. Note that this population represents a change from the 
protocol, which indicates that the ITT population will be used for the primary analyses. 
Intention to Treat (ITT) Population  
The intention to treat population includes all eligible, randomized participants.  All participants 
were assigned to the arm to which they were randomized irrespective of treatment received. 
This population will be used to conduct sensitivity analyses for the primary outcome and will be 
used as the main population for some secondary analyses. 
Per Protocol (PP) Population  
This population excludes all or part of the data obtained from any eligible, randomized 
participants who deliver at 20 weeks gestational age or greater that did not receive at least 90% 
of the full amount of intended randomized study therapy or are considered to have substantially 
deviated from the protocol in a manner that may impact study outcome or treatment receipt.  
The population also excludes individuals who were randomized after 10 weeks, 6 days 
gestational age.  Participants are grouped by actual treatment received. Treatment receipt 
reasons for exclusion and substantial deviations include:  
• Documented receipt of aspirin while on study outside of assigned study drug as 
identified by a reported protocol deviation 
• Not receiving treatment after randomization 
• Receipt of less than 90% of planned total doses after randomization where the number 
of planned doses will be calculated as those expected between randomization and the 
earliest of end of pregnancy and 36 0/7 weeks GA irrespective of if study drug 
administration was prematurely discontinued for any reason prior to that point 
For all analysis populations, data were analyzed as available with no imputation for missing 
outcomes except where specified for sensitivity analyses. 
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Drug Potency and Stability Information: Summary of stability analytical reports 
 
Morepen Laboratories Ltd. - Parwanoo 
 
Summary of Stability Analytical Reports 
 
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH) 
Lot: 1 (1) 
Mfg. date: 
09/2015 
Appearance Identification Dissolution 
Free 
Salicylic Acid 
(%) 
Assay 
(%) 
6 months Complies Complies Complies 1.27 100.59 
12 months Complies Complies Complies 1.59 99.85 
18 months Complies Complies Complies 1.93 98.79 
24 months Complies Complies Complies 2.12 98.23 
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results 
not presented here. 
Remarks: The sample is tested and found in compliance with the specification for the 
parameters tested under stability program. 
 
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH) 
Lot: 2 
Mfg. date: 
12/2016 
Appearance Identification Dissolution 
Free 
Salicylic 
Acid (%) 
Assay 
(%) 
6 months Complies Complies Complies 0.19 98.44 
12 months Complies Complies Complies 0.27 97.03 
18 months Complies Complies Complies 0.34 96.55 
24 months Complies Complies Complies 0.43 96.05 
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results 
not presented here. 
Remarks: The sample is tested and found in compliance with the specification for the 
parameters tested under stability program. 
 
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH) 
Lot: 3 
Mfg. date: 
10/2017 
Appearance Identification Dissolution 
Free 
Salicylic 
Acid (%) 
Assay 
(%) 
6 months Complies Complies Complies 0.14 101.32 
12 months Complies Complies Complies 0.39 100.26 
18 months Complies Complies Complies 0.76 99.10 
24 months      
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results 
not presented here. 
Remarks: The sample is tested and found in compliance with the specification for the 
parameters tested under stability program. 
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HELIX Pharma (Pvt.) Ltd. Quality Control Department 
Summary of Stability Analytical Reports 
 
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH) 
Lot: 1 
Mfg. date: 
11/2016 
Appearance Identification Disintegration Dissolution 
Free 
Salicylic 
Acid  
(%) 
Assay  
(%) 
6 months Complies Positive Complies Complies 0.78 98.15 
12 
months 
Complies Positive Complies Complies 1.21 99.47 
18 
months 
Complies Positive Complies Complies 1.36 98.43 
24 
months 
Complies Positive Complies Complies 1.38 98.14 
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results 
not presented here. 
Discussion: The 24 months stability reveals that all parameters are with in shelf life 
specification and no significant changes has been observed. Hence the stability at 300C ± 20C 
/ RH 65% ± 5% RH and 400C ± 2oC  / RH 75% ± 5% RH is satisfactory. 
 
Real Time Stability Studies (300C ± 20C / RH 65% ± 5% RH) 
Lot: 2 
Mfg. date: 
08/2017 
Appearance Identification Disintegration Dissolution 
Free 
Salicylic 
Acid  
(%) 
Assay  
(%) 
6 months Complies Positive Complies Complies 0.96 101.69 
12 
months 
Complies Positive Complies Complies 1.07 101.03 
18 
months 
Complies Positive Complies Complies 0.98 100.95 
Note: Accelerated studies (400C ± 2oC / RH 75% ± 5% RH) were also performed but results 
not presented here. 
Discussion: The 24 months stability reveals that all parameters are with in shelf life 
specification and no significant changes has been observed. Hence the stability at 300C ± 20C 
/ RH 65% ± 5% RH and 400C ± 2oC / RH 75% ± 5% RH is satisfactory. 
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Sensitivity Analyses for Primary Outcome 
Preterm delivery, n/N (%) Aspirin Placebo p-Value RR (95% CI) 
Analysis with inverse probability weighting1 - - <0.001 0.88 (0.82, 
0.94) 
ITT Population with multiple imputation2 - - - 0.87 (0.78, 
0.96) 
Per-Protocol Population3 537/4,927 (10.9) 600/4,861 (12.3) 0.020 0.89 (0.80, 
0.99) 
1 Relative risks, 95% confidence intervals and p-values are obtained from a binomial model with a log link 
adjusting for site, treatment and site by treatment interaction with inverse probability weighting. Includes 
negative outcomes for pregnancies excluded from primary analysis due to pregnancy outcome < 20 
weeks (n=350), medically terminated pregnancy ≥20 weeks (n=5), or otherwise missing outcomes ≥20 
weeks (n=9). 
2 Relative risks and 95% confidence intervals are obtained from a binomial model with a log link adjusting 
for site, treatment and site by treatment interaction for all randomized population with preterm status 
determined by gestational age for all pregnancies and multiple imputation for pregnancies with missing 
gestational age (n=45). 
3 P-values from Cochran-Mantel-Haenszel tests stratified by site. Relative risk and 95% confidence 
interval are obtained from a binomial model with a log link adjusting for site and treatment. 
 
 
 
 
